We also utilized mesenchymal-like MDA-MB-231 human breast cancer cells, in which TGF-β signaling is aberrantly activated, to determine whether OVOL2 also inhibits EMT phenotypes in MDA-MB-231 cells. Here, OVOL2 is linked to breast cancer.